Sage Therapeutics Rejects Biogen Offer

Posted by ISPE Boston
On February 19, 2025

In late January, Sage Therapeutics announced that its Board of Directors had unanimously rejected the unsolicited, nonbinding proposal it received from Biogen after concluding that the proposal significantly undervalues Sage and is not in the best interest of its shareholders. (Biogen had offered to acquire all outstanding shares of Sage for $7.22 per share.) In addition, the Board […]

Vertex gets FDA Okay for Non-Opioid Painkiller

Posted by ISPE Boston
On February 13, 2025

Vertex Pharmaceuticals has announced that the FDA has approved Journavx (suzetrigine) for the treatment of adults with moderate-to-severe acute pain, like the kind that follows surgery, accident or injury. Journavx is an effective, well-tolerated medicine without evidence of addictive potential. “Today’s approval is a historic milestone for the 80 million people in America who are prescribed […]

Anthos Acquired by Novartis for $925 Million

Posted by ISPE Boston
On February 13, 2025

Cambridge-based Anthos Therapeutics and its parent company, private investment platform Blackstone Life Sciences, have entered into an agreement with Novartis to acquire Anthos for up to $3.1 billion. Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel factor XI inhibitor […]

Take our GAMP Survey

Posted by ISPE Boston
On February 7, 2025

The ISPE GAMP Boston Community of Practice (CoP) is dedicated to providing valuable educational events, networking opportunities, and resources for professionals in the regulated life sciences industries. To ensure our upcoming events align with your interests, we’d love for you to take a quick survey. Your feedback is the key ingredient to our success! The Boston GAMP CoP is committed to fostering an environment where […]

Chapter Member Anniversaries: February 2025

Posted by ISPE Boston
On February 4, 2025

Please congratulate the following members celebrating milestone anniversaries in February 2025. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years John P. Alleruzzo Christopher E. Ames, Ames GMP Quality Solutions, LLC Kenneth A. Bradley, Pfizer Inc Kevin M. Chronley, A/Z Corporation William S. Crowe, BSME, BAPhysics, JD, Strawbridge […]

Welcome New Members January 2025

Posted by ISPE Boston
On February 4, 2025

We would like to introduce the Members who joined ISPE in January 2025, welcome them to the Chapter, and encourage them (and all our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And the […]

Empowering the Next Generation: Highlights from ISPE Boston’s 13th Annual Student Career Workshop

Posted by Brian Hagopian
On February 3, 2025

🌟 Exciting. Exhilarating. Empowering. Inspiring. 🌟 These were just a few of the words used to describe ISPE Boston’s 13th Annual Student Career Workshop, held this past weekend at Northeastern University. As the emcee of this incredible event, I had the privilege of witnessing firsthand the energy, ambition, and dedication of the next generation of life sciences professionals. Despite […]

A Water-ful Program at Alnylam

Posted by Brian Hagopian
On January 31, 2025

The importance and popularity of a cutting-edge educational program focused on pharmaceutical water was on full display at the chapter’s sold out January educational program, hosted by Alnylam Pharmaceutical’s at their Norton manufacturing facility. Alnylam generously opened their doors for an insightful tour of their central utility plant showcasing Alnylam’s distillation and membrane-based water for […]

MassBio Year-End Report Lauds VC Funding Increase

Posted by ISPE Boston
On January 16, 2025

In a sign of a biotech rebound, Massachusetts-headquartered biopharma companies received $7.89 billion in venture capital (VC) funding, marking the first year-over-year increase since the pandemic, according to a newly released year-end report from biopharma member organization MassBio. For the first time ever, the report also found that private biopharma companies based in Boston collected more venture […]

Lilly Acquires Scorpion Therapeutics’ Breast Cancer Program for $2.5 Billion

Posted by ISPE Boston
On January 16, 2025

Eli Lilly has agreed to acquire Scorpion’s PI3Kα inhibitor STX-478 which is currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors. STX-478 could represent the next generation of PI3Kα targeting agents by selectively targeting the pathway in cancerous but not healthy cells, thus overcoming a key limitation […]

Page 4 of 118«‹2 345 6 ›»